|
|
|
|
| Instant Update: Fri 18 May |
|
Ranbaxy gives away Trovas - Rewards "supporters" with free stock and 90% discount; Zelboraf boosts life expectancy - Extra time for terminal melanoma sufferers; Liver drug has two masters - Registration exposes split ownership
» full report |
|
| New boss for GlaxoSmithKline |
|
Breaking News - Weds 16 May: GlaxoSmithKline has appointed its former Sales Director for Australia to run the local operation following the departure of Deborah Waterhouse
» full report |
|
| Lipitor copies to flood June PBS |
|
Just as Pfizer mounts a rear-guard action to stop patients being steered away from Lipitor, additions to the PBS on June 1 will include numerous new brands of the cholesterol-lowerer plus a number of new generic substitutes for other out-of-patent drugs
» full report |
|
| Profit boost for AstraZeneca |
|
The turnaround in demand that last year saved AstraZeneca's Sydney factory from closure contributed to a 160% rise in after-tax profit for the company in 2011 despite sales revenue being lower than the previous year
» full report |
|
| High Court denies Efexor appeal |
|
Pfizer has been denied leave to appeal to the High Court in the Efexor-XR case, vindicating generic competitors' decision to flock into the marketplace after their surprise win in the Federal Court last year
» full report |
|
| Code panel firms up new disclosures |
|
Disclosure of total payments to and financial support for healthcare professionals from pharma companies is very likely to be part of the new Medicines Australia Code of Conduct but naming the individuals who receive the benefits appears to be some years away a Code Review Panel document shows
» full report |
|
| Biota sticks to local job plans |
|
Despite merging with US based Nabi Biopharmaceuticals and de-listing in Australia, anti-viral drug developer Biota is to go ahead with the creation of 35 new research and development jobs here, says the Victorian Government
» full report |
|
| Latest ARTG registrations |
|
In a relatively subdued week on the drugs register, Roche registered a new presentation of flu anti-viral Tamiflu and Hospira added to the potential generic competitors for Roche's zoledronic acid
» full report |
|
|
|
|
|
|
|
|
- Roche ends heart drug program - 'Good cholesterol' booster called off - » full report
- Revlimid shows promise for maintenance - Extends survival in multiple myeloma - » full report
- New pain uses elude Pfizer's Lyrica - No success in HIV or diabetes pain - » full report
- Latest clinical trial results - Trial outcomes from journals and meetings - » full report
|
|
|
| © 2007 Lush Media | Privacy Statement | Subscribe to Pharma in Focus | Design: Jolly Good Design
|